Tolcapone (Tasmar)

A benzophenone and nitrophenol compound that acts as an inhibitor of CATECHOL O-METHYLTRANSFERASE, an enzyme involved in the metabolism of DOPAMINE and LEVODOPA. It is used in the treatment of PARKINSON DISEASE in patients for whom levodopa is ineffective or contraindicated.

Also Known As:

Tasmar; 3,4-Dihydroxy-5'-methyl-5-nitrobenzophenone; Ro 40-7592; Ro-40-7592; SOM0226; 3,4 Dihydroxy 5' methyl 5 nitrobenzophenone; Ro 40 7592; Ro 407592; Ro407592; Methanone, (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)-

Networked: 194 relevant articles (21 outcomes, 42 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 133

Experts

1.	Eggert, Karla: 3 articles (10/2022 - 05/2010)
2.	Kayser, Andrew S: 3 articles (12/2021 - 01/2017)
3.	Grant, Jon E: 3 articles (01/2021 - 01/2011)
4.	Müller, Thomas: 3 articles (01/2018 - 06/2006)
5.	Oertel, Wolfgang H: 3 articles (01/2014 - 01/2008)
6.	Haasio, Kristiina: 3 articles (01/2010 - 10/2002)
7.	Waters, Cheryl: 3 articles (12/2007 - 05/2003)
8.	Fotteler, B: 3 articles (06/2000 - 01/2000)
9.	Li, Li: 2 articles (01/2022 - 08/2013)
10.	Vega, Taylor A: 2 articles (12/2021 - 10/2020)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 01/01/2010 - "Adjunctive tolcapone treatment was associated with statistically significant improvement in QOL in fluctuating Parkinson's disease patients. " 01/01/2014 - "Under routine practice conditions, tolcapone was shown to be safe and effective in patients with Parkinson disease. " 01/01/1990 - "Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease." 01/01/2018 - "The aim of the study was to investigate the efficacy of homemade tolcapone in treatment of patients with Parkinson's disease (PD). " 07/01/2009 - "Safety and efficacy of tolcapone was studied in 237 patients with advanced Parkinson's disease (PD) in a prospective, open-label, multicenter, non-interventional trial. "
2.	Parkinsonian Disorders (Parkinsonism) 05/01/1998 - "Tolcapone appears to be beneficial in the treatment of patients with parkinsonism who have not yet developed motor fluctuations." 09/01/1997 - "Tolcapone appears to be beneficial in the treatment of patients with parkinsonism who have not yet developed motor fluctuations." 04/01/2006 - "(4) Placebo-controlled trials show that first-line treatment with tolcapone 100 mg to 200 mg 3 times a day reduces the duration of motor freezing ("off") periods, but the global impact of tolcapone on parkinsonism appears to be limited. " 03/01/2000 - "Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism." 03/01/2000 - "The effect and clinical significance of tolcapone withdrawal on erythrocyte catechol-O-methyltransferase (COMT) activity, levodopa pharmacokinetics, and levodopa requirements were investigated in 59 patients with fluctuating parkinsonism who were randomized to receive placebo or tolcapone 100 or 200 mg three times daily for 6 weeks. "
3.	Alcoholism (Alcohol Abuse) 10/01/2022 - "Effects of pharmacological and genetic regulation of COMT activity in alcohol use disorder: a randomized, placebo-controlled trial of tolcapone." 10/01/2020 - "The catechol-O-methyltransferase inhibitor tolcapone modulates alcohol consumption and impulsive choice in alcohol use disorder." 01/01/2024 - "Catechol-O-Methyltransferase inhibition and alcohol use disorder: Evaluating the efficacy of tolcapone in ethanol-dependent rats."
4.	Schizophrenia (Dementia Praecox) 04/01/2011 - "It will soon be understood if tolcapone represents one of the first hypothesis-driven, biology-based, genotype-specific, targeted treatments of cognitive and negative symptoms of schizophrenia." 04/01/2011 - "Tolcapone, COMT polymorphisms and pharmacogenomic treatment of schizophrenia." 12/01/2009 - "Tolcapone could be potentially useful in the treatment of conditions with deficient sensorimotor gating and working memory such as schizophrenia and prodromal states but only in a genotype-specific manner." 06/09/2004 - "The interaction between clozapine and tolcapone may have implications for the treatment of schizophrenia."
5.	Prodromal Symptoms 12/01/2009 - "Tolcapone could be potentially useful in the treatment of conditions with deficient sensorimotor gating and working memory such as schizophrenia and prodromal states but only in a genotype-specific manner."

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	Catechol O-Methyltransferase (Methyltransferase, Catechol)
3.	entacapone (Comtan)
4.	Selegiline (E250)
5.	Ethanol (Ethyl Alcohol)
6.	iododiflunisal
7.	Carbidopa (Lodosyn)
8.	Dopamine Agonists (Dopamine Agonist)
9.	Therapeutic Uses
10.	Benserazide

Related Therapies and Procedures

1.	Therapeutics
2.	Activities of Daily Living (ADL)
3.	Transjugular Intrahepatic Portasystemic Shunt
4.	Intravenous Administration
5.	Induced Hypothermia